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A RelA(p65) Thr505 phospho-site mutation reveals an
important mechanism regulating NF-κB-dependent
liver regeneration and cancer
A Moles1,4, JA Butterworth2,4, A Sanchez2,4, JE Hunter2, J Leslie1, H Sellier2, D Tiniakos1, SJ Cockell3, DA Mann1, F Oakley1
and ND Perkins2
Post-translational modifications of nuclear factor (NF)-κB subunits provide a mechanism to differentially regulate their activity in
response to the many stimuli that induce this pathway. However, the physiological significance of these modifications is largely
unknown, and it remains unclear if these have a critical role in the normal and pathological functions of NF-κB in vivo. Among these,
phosphorylation of the RelA(p65) Thr505 residue has been described as an important regulator of NF-κB activity in cell lines, but its
physiological significance was not known. Therefore, to learn more about the role of this pathway in vivo, we generated a knockin
mouse with a RelA T505A mutation. Unlike RelA knockout mice, the RelA T505A mice develop normally but exhibit aberrant
hepatocyte proliferation following liver partial hepatectomy or damage resulting from carbon tetrachloride (CCl4) treatment.
Consistent with these effects, RelA T505A mice exhibit earlier onset of cancer in the N-nitrosodiethylamine model of hepatocellular
carcinoma. These data reveal a critical pathway controlling NF-κB function in the liver that acts to suppress the tumour-promoting
activities of RelA.
Oncogene advance online publication, 8 February 2016; doi:10.1038/onc.2015.526
INTRODUCTION
The nuclear factor (NF)-κB transcription factor family are important
regulators of immune and inflammatory responses.1 Furthermore,
aberrantly active NF-κB is associated with many human diseases,
including cancer.2–4 While the pathways leading to nuclear
translocation of NF-κB provide a primary level of regulation of
its activity, NF-κB subunits are also subject to a wide range of post-
translational modifications (PTMs). These can contribute to the
control of nuclear translocation, but also have major effects on
the function of NF-κB subunits, including induction of protein
degradation, enhancement of DNA binding, as well as transcrip-
tional effects, such as stimulation or inhibition of coactivator/
corepressor binding.5–7 PTMs provide a mechanism to differen-
tially regulate the transcriptional activity of NF-κB in response to
diverse stimuli in different cell types.4
The C-terminal RelA (p65) transactivation domain is responsible
for mediating most of this NF-κB subunit’s transcriptional effects
and contains a number of highly conserved known and putative
phosphorylation sites.6 It has been suggested that different
patterns of phosphorylation of these sites can control the
specificity of NF-κB target gene activation or repression.4,8 This
can result in different context-dependent functions of NF-κB. A
good example of this is the RelA-dependent anti-apoptotic effects
seen following treatment with inflammatory stimuli, such as tumor
necrosis factor (TNF)-α that contrast with pro-apoptotic effects
following treatment with some DNA damage agents.9–14 Under-
standing the mechanistic basis for these contrasting effects has
important implications for the role of NF-κB in tumorigenesis and
the response to cancer therapies.4
Among these pathways, phosphorylation of the RelA(p65)
Thr505 residue (Figure 1a) provides a mechanism of crosstalk
between NF-κB signalling and DNA replication stress. Our group
had previously observed that phosphorylation of RelA at Thr505
by Chk1 correlated with a pro-apoptotic form of NF-κB in response
to cisplatin treatment and following induction of the ARF tumour
suppressor.11,12,15,16 Additionally, we found that RelA Thr505
phosphorylation negatively regulates diverse cellular functions,
such as proliferation, migration and autophagy.12 These data
suggested that Thr505 mutation would remove the functions of
RelA associated with tumour suppressor characteristics, resulting
in a form of RelA with enhanced tumour-promoting activities,
including the abilities to promote cell survival and proliferation.
However, in common with many other NF-κB subunit PTMs, in vivo
evidence for such an important functional role has been lacking.
Therefore, to address this, we have generated a knockin mouse
mutant where the RelA Thr505 residue has been changed to
alanine. We hypothesised that selectively removing a specific
mechanism of regulating NF-κB would provide important func-
tional insights not seen with whole-gene deletion, where due to
the pleiotropic functions of this pathway subtler effects
are masked. In this report, we have investigated the effect of
this mutation on the response to liver injury and chemically
induced hepatocellular carcinoma, both processes requiring NF-κB
activity.17–21 We find that mutation of RelA Thr505 leads to an
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aberrant proliferative response after liver injury and earlier onset
of hepatocellular carcinoma, revealing an important mechanism
normally acting to suppress the tumour-promoting functions
of NF-κB.
RESULTS
Creation of the RelA T505A knockin mouse
Although studies based on cell lines have indicated an important
regulatory role for RelA Thr505 phosphorylation, the significance
of this modification in vivo is not known. Therefore, to answer this
question, a C57Bl/6 mouse was generated where this residue was
mutated to alanine. By contrast with RelA knockout mice, which
die in utero as a result of TNF-induced liver apoptosis,9 RelA T505A
mice were healthy with no overt effects on ageing or mortality up
to 18 months of age (not shown). The absence of an effect on
viability is consistent with previous observations from this group,
where mutation of this site was determined not to affect
TNF-induced NF-κB activity or survival.12 Analysis of the organs
from 12-week-old littermates revealed no statistically significant
differences in the weight of the liver, heart and kidneys (Figure 1b;
Supplementary Figures S1A and B). Furthermore, no differences in
the levels of RelA or other NF-κB subunits were seen in the liver
(Figure 1c; Supplementary Figure S1C), while no overt differences
in the TNF response were observed in hepatocytes prepared
from wild-type (WT) and RelA T505A mice when IκBα degradation,
RelA Serine 536 phosphorylation and nuclear translocation were
analysed (Figure 1d; Supplementary Figure S1D).
The RelA T505A mouse reveals a role for RelA as a regulator of
hepatocyte proliferation following partial hepatectomy
Following 70% partial hepatectomy in mice, the liver
rapidly regenerates over a period of 5 days with peak cellular
proliferation occurring after 36 h.17 In this model, a wave of highly
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Figure 1. The phenotype of RelA T505A mice. (a) Schematic diagram of RelA showing the location of the Thr505 residue in transactivation
domain 2. (b) Liver body weight ratio of wild type (WT), WT/T505A and T505A 12-week-old littermate mice. WT, n = 4 males, 8 females; WT/
T505A, n= 2 males, 5 females; T505A, n= 4 males, 5 females. Data represent mean± s.e.m. (c) Western blots showing relative levels of NF-κB
subunits in WT and RelA T505A mice. (d) Western blot analysis of phospho-S536 RelA, RelA, IκB-α and β-actin from WT and RelA T505A
hepatocytes. Hepatocytes were cultured in 0% FBS media and treated with 50 ng/ml of TNF-α for 10 or 30 min before preparation of cell
lysates. Lanes represent independent experimental replicates from a single hepatocyte isolation. These results are representative of data from
three separate hepatocyte preparations. In this and subsequent experiments, all mice were designated to an experimental group dependent
on their strain. NS, not significant.
RelA T505 regulates liver regeneration and cancer
A Moles et al
2
Oncogene (2016) 1 – 10 © 2016 Macmillan Publishers Limited
synchronised hepatocyte cell-cycle entry occurs within hours as a
consequence of the mechanical stress placed on the remnant
liver, an increase in priming cytokines and growth factors,
together with the requirement to maintain the mouse's metabolic
demands. This process depends on NF-κB, although a recent
report suggested that the RelA subunit was dispensable for liver
regeneration.22,23 However, subunit deletions can allow compen-
sation by other NF-κB family members.24 By contrast, a knockin
mutation that selectively removes one mechanism of regulation
will behave differently if that pathway plays an important role in
the process under study. Previous characterisation of RelA
phosphorylation at Thr505 by Chk1 had implied a role in the
cellular response to DNA replication stress.12 We were therefore
interested in whether mutation of this site would affect
proliferative responses in vivo. To address this, we investigated
the response of WT and RelA T505A mice in a model of 70% partial
hepatectomy.
Consistent with our hypothesis that mutation of RelA Thr505
would affect liver regeneration, male RelA T505A mice had a
higher liver to body weight ratio relative to WT mice 36 h
following hepatectomy (Figure 2a). Moreover, PCNA staining,
mitotic body counts and BrdU incorporation analysis, all markers
of cellular proliferation, showed higher levels in RelA T505A mice
that extended to 72 h post hepatectomy (Figures 2b and c and
Supplementary Figure S2A). This aberrant proliferation was
associated with enhanced levels of γH2AX staining, a marker of
DNA damage, together with raised levels of p53 protein and
phospho-JNK (Figures 2d and e). 4-Hydroxy-2-nonenal staining
revealed no significant increases (Supplementary Figure S2B),
indicating that the increased replication stress and not enhanced
levels of reactive oxygen species or liver peroxidation was the
probable cause of this DNA damage response. These conclusions
were supported by gene expression profiling of liver tissue
samples before and 36 h after partial hepatectomy. Analysis of
these data did not reveal a statistically significant gene signature
associated with the T505A mutation (not shown), suggesting
either that the effects seen result from the cumulative effects of
relatively small increases in a large number of NF-κB target genes
and are restricted to a subpopulation of cells, or that the effects of
the Thr505 mutation occur at an earlier time point. However, gene
set enrichment analysis (GSEA) revealed a significant upregulation
of genes associated with proliferation and the cell cycle at 36 h
post hepatectomy (Figure 2f and Supplementary Figure S2C).
Moreover, consistent with the γH2AX analysis and raised p53
levels, significant induction of gene sets associated with DNA
repair and replication was also observed (Figure 2f and
Supplementary Figures S2C and D). Together these results
demonstrate that RelA Thr505 phosphorylation provides an
important regulatory mechanism to control the proliferative
response and prevent cellular and genomic damage.
RelA T505 regulates the response to acute and chronic liver injury
To confirm and extend this analysis, we investigated the response
of mice to acute and chronic chemical liver injury with the
potent hepatotoxin carbon tetrachloride (CCl4). CCl4 is metabo-
lised primarily by the enzyme CYP2E1 in the liver to •CCl3, a
trichloromethyl radical and a single IP dose of CCl4 will cause
hepatocyte death, inflammation, activation of hepatic myofibro-
blasts and a compensatory asynchronous hepatocyte proliferation,
which peaks after around 72 h. Following acute CCl4 administra-
tion, no significant differences in liver injury (as shown
by elevation of serum transaminases), liver to body weight
ratio, or hepatic myofibroblast activation (αSMA staining) was seen
between WT and RelA T505A mice (Figure 3a and Supplementary
Figures S3A and B). However, once again we observed a
significant increase in markers of cell proliferation in RelA T505A
mice (Figures 3b and c and Supplementary Figure S3C).
Similar results were seen following chronic CCl4 administration.
Here, after 8 weeks there was once again no change in liver body
weight ratio, but significantly higher levels of markers of cell
proliferation were again observed (Figure 4a and Supplementary
Figure S4A). By contrast with the acute CCl4 model, chronic CCl4
administration resulted in a reduction in scar-forming hepatic
myofibroblasts in RelA T505A mice, which was associated with a
reduction in fibrosis, as assessed by sirius red staining for collagen
(Figures 4b and c). Although reduced levels of liver injury were
also seen in RelA T505A mice, these were not statistically
significant (Supplementary Figure S4B).
Earlier onset of liver cancer in RelA T505A mice
Previous in vitro studies of RelA Thr505 phosphorylation had all
pointed to this modification providing a mechanism to suppress
the tumour-promoting functions of RelA.11,12,15,16 The data from
partial hepatectomy and liver injury models above, where
consistently higher levels of cell proliferation, accompanied by
higher levels of DNA damage were seen in RelA T505A mice, were
all consistent with this hypothesis. We therefore next investigated
if RelA T505A mice would exhibit earlier onset of tumorigenesis in
the N-nitrosodiethylamine (DEN) model of hepatocellular
carcinoma.25 DEN is a DNA alkylating agent and so we first
investigated whether acute administration, which promotes
hepatocyte death followed by compensatory proliferation,
resulted in any observable differences between WT and RelA
T505A mice. Consistent with earlier data, an enhanced prolifera-
tive response was observed in RelA T505A mice, with no
differences in liver/body weight ratio and only a small difference
in liver damage being seen after 72 h (Figure 5a and
Supplementary Figures S5A and C). This result suggested that
RelA T505A mice could display differences in tumour develop-
ment following DEN treatment. DEN was, therefore, administered
to 15-day-old WT and RelA T505A mice and tumour growth was
evaluated after 30 weeks. At this point tumours start to become
visible on the liver surface in WT mice and therefore this is the
optimal time to investigate if the RelA T505A mutation resulted in
earlier onset of tumorigenesis. Analysis of these tumours revealed
that both homozygous and heterozygous RelA T505A mice had
significantly higher numbers of visible liver tumours (Figure 5b).
Moreover, RelA T505A mice were more likely to display large
(45 mm diameter) tumours (6/12 for homozygotes, 2/9 for
heterozygotes) compared to WT mice, where none were seen at
this time point (0/13) (Figure 5c).
More detailed histological analysis of liver tissue sections by an
expert pathologist confirmed the visible differences in tumour
numbers between RelA T505A mice and WT mice (Figure 5d and
Supplementary Table T1). Interestingly, while the numbers of
adenomas are broadly equivalent between the two mice strains
(16 foci from 13 WT mice, 12 foci from 12 RelA T505A mice), the
hepatocellular carcinoma numbers were dramatically different.
Here the 12 RelA T505A mice had 27 hepatocellular carcinoma
versus only three seen in the WT mice (Figure 5d; Supplementary
Figure S5D and Supplementary Table T1). Although NF-κB
can promote the development of inflammation-associated
cancers,2,18,21 no differences in the levels of inflammation
or fibrosis were observed between WT and RelA T505A mice
(Supplementary Table T1). Consistent with this, when we
examined cytokine serum levels in mice from the DEN model by
multiplex ELISA, the only one to show a significant difference in
the RelA T505A mice was KC/GRO (CXCL1), a cytokine primarily
expressed by macrophages, where levels were significantly raised
(Supplementary Figure S6). Q-PCR analysis of tumour tissue from
DEN-treated livers did not show a statistically significant increase
in KC/GRO mRNA levels in RelA T505A mice, although there was a
trend towards higher levels (Supplementary Figure S6J). Although
interleukin-6 levels were raised in a few RelA T505A mice, overall
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the results were not significant. No changes were seen with TNFα,
interleukin-1β and other cytokines examined. Therefore, together
with there being no indication of changes in inflammation
associated with the DEN tumours in RelA T505A mice,
we conclude that the effects we see on tumour growth do not
primarily arise through an inflammatory mechanism, although we
cannot rule out a potential role for KC/GRO.
Although broadly similar to WT mice, the background liver of
RelA T505A NF-κB knockin mice did show less severe DEN-induced
fibrotic injury (stage 2 fibrosis in all cases versus mixed stage 2
(6/13) to stage 3 (7/13) in WT mice). There was also increased
steatosis in RelA T505A mice (mild to severe in 10/12 cases of
macrovesicular or mixed type versus mild to moderate macro-
vesicular or mixed steatosis without steatohepatitis in 7/13 cases
of WT mice) (Supplementary Table T1).
Further analysis of these tumours revealed overall lower levels
of apoptosis, but increased levels of proliferation in DEN-treated
livers from RelA T505A mice (Figures 6a and b; Supplementary
Figures S7A and B). Furthermore, interesting differences in the
activity of cell signalling pathways was observed between tumour
and non-tumour tissue. Here, reduced levels of phospho-ERK and
phospho-JNK signalling were seen in extracts from non-tumour
tissue, while the opposite was found in tumour samples
(Figure 6c). JNK activity in the liver has been linked to cancer,
fibrosis and steatosis.17,26 Consistent with this raised level of JNK
activity in tumours, a modest but significant increase in the mRNA
levels of MKK7 (mitogen-activated protein kinase kinase 7), a
kinase known to activate JNK signalling in the liver, was seen
(Figure 6d).17,27 No significant effect was seen with the related
kinase MKK4, although some RelA T505A tumour samples
did display higher levels (Figure 6e). By contrast, although
NF-κB-dependent control of JNK activity in the liver has been
linked to regulation of its target gene Gadd45β,17 we did not
observe any changes in its expression in RelA T505A tumours
(Figure 6f).
Taken together, these results demonstrate that the T505A
mutation results in a more tumour-promoting form of RelA that
leads to the earlier onset of more aggressive hepatocellular
carcinoma.
DISCUSSION
Here we have demonstrated that RelA Thr505 phosphorylation is
an important physiological regulator of NF-κB function in the liver.
Modification of this site provides a mechanism to antagonise and
limit aspects of RelA function associated with its tumour-
promoting activities (Figure 7). Although PTMs of RelA have been
highly studied, little is known about their physiological roles.
Moreover, most attention has been focused on a relatively small
subset of these modifications, whereas the range of PTM types
and number of sites capable of being modified is very high.4,7 This
diversity provides a mechanism to control the functional
consequences of NF-κB activation by allowing selective regulation
of NF-κB gene targets.
In vitro analysis of these modifications is hampered by
the problems associated with subunit overexpression or non-
physiological responses associated with the analysis in cancer cell
lines. Therefore, to learn more about the significance of RelA
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Thr505 phosphorylation, we created a knockin mutant mouse.
Study of the RelA subunit in adult animals has been hampered by
the lethality of the gene knockout resulting from TNF-induced
liver apoptosis.9 Although an increasing number of studies have
employed a conditional knockout of RelA (for example Ringelhan
et al.,23 Algul et al.,28 Stein et al.29) a consequence of this is that
much is still not known about RelA function in mature mice, with
many assumptions being based on the effect of IKK mutants that
are now known to have a variety of NF-κB independent
functions.30 Moreover, gene knockouts inactivate a wide range
of functions that can potentially mask other, subtler but still
important effects. For example, the RelA knockout has no effect in
the partial hepatectomy model, while our T505A knockin
does22,23 (Figure 2). To date, the only other published analysis of
RelA phospho-site knockin mutant mice involves analysis of the
Ser276 residue. The effect of mutating this site to alanine resulted
in a form of RelA that functions as a transcriptional repressor.31
This resulted in gene repression leading to embryonic death at
different stages due to variegated developmental abnormalities.31
However, this site is functionally distinct from the Thr505 residue,
with this latter modification not being required for nuclear
translocation or gene activation in response to inflammatory
stimuli.11,12,16 Rather, it provides a mechanism through which
certain types of DNA damage, such as replication stress,
antagonise NF-κB activity. However, in vivo evidence for the
importance of this pathway was lacking. Here, we have
established the functional importance of this pathway in vivo.
We demonstrate that in the liver the response to injury has
an important modulatory effect on NF-κB, suppressing the
pro-proliferative functions associated with NF-κB's tumour-
promoting abilities (Figure 7). We propose that further knockin
mutagenesis of RelA and other NF-κB subunits will provide a
clearer route to define its role in vivo and reveal unknown
functions not seen in previous mouse models.
In addition to an increase in proliferation, other effects were
also observed, such as a reduction in fibrosis in RelA T505A mice
with the chronic CCl4 model (Figure 4). This effect is likely to be a
consequence of reduced numbers of scar-forming cells, but we do
not exclude the possibility that there could be an inflammatory
contribution to the phenotype. An increase in steatosis was also
seen in the livers of RelA T505A mice in the DEN model
of hepatocellular carcinoma. Steatosis has been linked with
increased susceptibility to liver cancer, even in the absence of
fibrosis.32 This hepatic lipid accumulation can induce metabolic
changes, increase reactive oxygen species production and induce
signalling pathways including JNK.26 The combination of steatosis
and increased hepatocyte proliferation may cooperate to accel-
erate tumour development in the RelA T505A NF-κB knockin mice.
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Given the effect of the RelA T505A mutation, it might be
expected that this site or region of the RelA transactivation
domain would be also mutated in human cancer or that SNPs in
this region would predispose to liver or other diseases. However,
analysis of the literature or the Catalogue of Somatic Mutations in
Cancer (http://cancer.sanger.ac.uk/cosmic) database demonstrates
very few alterations in the motif containing RelA Thr505 (not
shown). But alterations in the coding sequence of RelA and other
NF-κB subunits, despite their involvement in many diseases, are
very rare.4 This may be a reflection of the NF-κB response having
many different functional elements and so subunit mutations
would have the effect of enhancing certain aspects of NF-κB
behaviour at the expense of others. Consequently, if a tumour
requires the overall NF-κB response to promote its growth and
survival, such mutations would not be selected. Therefore, while in
the context of an experimental system, such as those used here,
we see effects that enhance tumorigenesis, in reality there may be
negative consequences, that mean such mutations have an overall
detrimental effect on the tumour.4
We have not yet been able to demonstrate phosphorylation of
the Thr505 in liver tissue. This may reflect the relatively poor
quality of phospho-specific antibodies to this site. Alternatively,
phosphorylation of this site may either be very labile and lost
during the process of making protein extracts from the liver, be
restricted to a limited to a subpopulation of cells or be specific to a
cell cycle stage.
An important question for future studies will be whether this
mutation affects a specific and common set of target genes in all
cell types or whether any effects on gene expression are context
dependent. Moreover, as our analysis of gene expression
following partial hepatectomy did not reveal gene-specific effects,
it is possible that this site exerts a modulatory effect on multiple
NF-κB targets, the cumulative effect of which leads to the changes
in cell behaviour. Alternatively, these effects might be restricted to
a subset of liver cells or a specific time point in the experimental
procedure. Nonetheless, we have established for the first
time in vivo the importance of the RelA Thr505 motif for both
chemical and surgically induced liver regeneration together with
carcinogen-induced hepatocellular carcinoma.
MATERIALS AND METHODS
Mice
All experiments were approved by Newcastle University’s Animal Welfare
and Ethical Review Board. Animals were bred in the Newcastle University
animal unit, maintained as specific pathogen free according to the FELASA
Guidelines. Work was carried out under project and personal licences
approved by the Home Office. Transgenic RelA T505A mice were
generated by Taconic Artemis (Cologne, Germany) using C57Bl/6 ES cells.
All mice were maintained on a pure C57BL/6 background. No blinding of
groups in mouse studies was performed. All mice were designated to an
experimental group dependent on their genotype.
Genotyping of RelT505A/T505A mice
Genotyping was performed by polymerase chain reaction using genomic
DNA isolated from ear clips. The WT or RelT505A/T505A alleles were ampli-
fied using Eurogentec forward 5ʹ-AGCCATGCTCCTGTCAAACC-3ʹ and
reverse 5ʹ-CAGGGATTATTTAGTCCCTTGG-3ʹ specific primers for 35 cycles;
denaturation: 95 °C, 30 s; annealing: 56 °C, 40 s; extension: 72 °C, 1 min).
Amplification of a single product of 241 or 360 bp corresponds to
WT or T505A+/+ allele, respectively.
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Figure 5. Early and increased onset of hepatocellular carcinoma in RelA T505A mice following DEN administration. (a) Mean number of cells/
field scoring positive for PCNA in WT and T505A liver tissue sections following 24, 48 or 72 h of acute DEN administration. (b) Numbers of
macroscopic tumours visible in WT and T505A livers 30 weeks after DEN administration. (c) Representative images of livers in WT and T505A
livers 30 weeks after DEN administration. RelA T505A livers show large (45 mm) tumours, summarised in the table shown. (d) Histological
quantification of tumours into hepatocellular ademonas and carcinoma in liver sections from DEN-treated WT and T505A mice. An expert
pathologist scored all pathology. *Po0.05, **Po0.01 (Unpaired Student's t-test).
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Murine hepatocyte isolation
Mouse primary hepatocytes were isolated from aged-matched 8–12 weeks
WT and RelA T505A males as described.33 Hepatocytes were washed
and media was changed to 0% FBS 3–4 h after isolation. TNF-α 50 ng/ml
(Peprotech, London, UK) treatment was performed ~ 20 h post isolation for
10 or 30 min.
Immunofluorescence
WT and RelA T505A hepatocytes were cultured in collagen I-coated glass
coverslips, fixed with formalin and permeabilised with 0.1% saponine/0.5%
BSA solution. After blocking with 3% BSA, RelA antibody was added for
120 min. After washing, secondary donkey anti-rabbit Alexa 594 (Invitrogen,
Paisley, UK) was incubated for 60 min. Coverslips were mounted with
ProLong Diamond DAPi-conjugated mounting medium (A-21207, Invitrogen).
Pictures of slices with 0.5 μm thickness were taken using a Multiphoton
Nikon (Kingston upon Thames, UK) A1 confocal microscope at ×600 oil. An
electronic zoom of magnification 1.8 was made of a region of interest. Image
analysis was performed using Image J software (NIH, Bethesda, MA, USA).
Partial hepatectomy
Seventy percent liver partial hepatectomy (PhX) was performed on
10–12-week-old male littermates as previously described.34 At 36 h, 72 h
and 5 days following PhX, the mice were humanely killed and liver tissue
was harvested. Appropriate pain relief was given.
In-vivo models of liver injury
For acute CCl4 treatment, WT and T505A 8–10-week-old male littermates
were injected intraperitoneally (IP) with CCl4 at a dose of 2 μl (CCl4:olive oil,
1:1 [v:v])/g body weight). Acute DEN, 8-week-old mice were given 80 mg/
kg intraperitoneal injection to induce liver DNA damage. Mice were
humanely killed, then liver and serum were harvested at 24, 48 and 72 h.
For chronic CCl4 treatment, 8–12 week old male wt and T505A male
littermate mice were injected with CCl4 intraperitoneally (IP) twice a week
at a dose of 2 μl (CCl4:olive oil, 1:3, [v:v])/g body weight during 8 weeks.
Mice were humanely killed, then liver and serum was harvested. Serum
transaminases were measured in the Clinical Biochemistry department at
the Royal Victoria Infirmary, Newcastle.
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Figure 6. Altered apoptosis and ERK/JNK signalling in DEN-treated livers from RelA T505A mice. (a, b) Mean number of cells/field scoring
positive for active Caspase 3 (a) and PCNA (b) in WT and T505A livers 30 weeks after DEN administration. (c) Western blots with antibodies
against total or phospho-Thr183/Tyr185 JNK, total or phospho-Thr202/Tyr204 ERK and total or phospho-Thr180/Tyr182 p38 kinases in tumour
and non-tumour tissue from three different WT and T505A livers 30 weeks after DEN administration. (d–f) RT-qPCR data showing relative
MKK7 (c), MKK4 (d) and Gadd45β (b) mRNA expression tumour tissue from WT and T505A livers 30 weeks after DEN administration. Data
represent mean± s.e.m.; each point is an individual mouse. *Po0.05, **Po0.01 (Unpaired Student's t-test).
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In-vivo models of liver cancer
Day 15 mice were given 30 mg/kg DEN in 0.9% saline by IP injection to
induce liver cancer. Mice were humanely killed, and liver and serum were
harvested at 30 weeks post DEN. Serum transaminases were measured in
the Clinical Biochemistry department at the Royal Victoria Infirmary,
Newcastle.
Immunohistochemistry
Formalin-fixed paraffin-embedded liver sections were dewaxed and
hydrated. Endogenous peroxidase activity was blocked with hydrogen
peroxide and antigen retrieval was achieved using 1 mM EDTA for γH2A.X,
10 mM sodium citrate buffer, pH 6.0 for active caspase 3 and BrdU and
0.0005% Trypsin for 20 min at 37 °C and PCNA. Tissue was blocked using
an Avidin/Biotin Blocking Kit (Vector Laboratories, Peterborough, UK)
followed by 20% swine serum in PBS and then incubated with primary
antibodies overnight at 4 °C. The next day slides were washed and
incubated with biotinylated swine anti-rabbit followed by Vectastain Elite
ABC Reagent (Peterborough, UK). Antigens were visualised using DAB
peroxidase substrate kit and counterstained with Mayer’s hematoxylin.
Immuno-stained cells were manually counted and expressed as the mean
number of positive cells per field in 15 high-power fields at × 20
magnification or 10 fields at × 10 magnification. For all histological studies,
the stained slides were blinded (coded) prior to analysis.
H&E and Sirius Red. Formalin-fixed and paraffin-embedded sections
were dewaxed, hydrated and then stained with either H&E or 0.1% Sirius
Red Picric solution following standard procedures.
Multi-SPOT Assay System (MSD) V-PlexTM serum analysis
Serum for 10× WT and 10 × RelA T505A 30-week-old-DEN-injected
animals were analysed for cytokine levels in triplicate using the MSD V-Plex
assay system. Samples were diluted 1:2 and incubated overnight. The assay
was performed according to the manufacturer’s instructions.
Cell extracts for western blotting
Mouse liver tissue was homogenised in Phosphosafe extraction buffer
(Millipore, Watford, UK) following manufacturer's protocols in Precellys 24
ceramic mix bead tubes (Stretton Scientific Ltd, Stretton, UK) in a Precellys
24 homogeniser (Stretton Scientific Ltd) at 6500 r.p.m. for 30 s. BCA
(Thermo Scientific Ltd, Loughborough, UK) analysis was performed to
normalise protein concentration.
Quantitative PCR
Quantitative PCR was performed as described previously.35 Qiagen
Quantitect primer assays were used for RT-qPCR analysis of genes of
interest. Housekeeping control Gapdh primers were from Eurogentec
(forward 5′-GCTACACTGAGGACCAGGTTG-3′ and reverse 5′-GCCCCTCCT
GTTATTATGGGG-3′).
Microarray analysis
Total RNA was extracted from snap-frozen livers samples from control and
36-h PhX livers. Briefly, frozen samples were homogenised using
Precellys 24 ceramic mix bead tubes (Stretton Scientific Ltd) in a Precellys
24 homogeniser (Stretton Scientific Ltd) at 6500 rpm for 30 s according to
the Qiagen RNeasy mini kit instruction manual. After, samples were passed
through Qiashredders (Qiagen, Crawley, UK) and RNA was purified
following instructions from the Qiagen RNeasy mini kit. Microarray analysis
was performed by Cambridge Genomic Services.
Bioinformatics analysis
The Illumina mouse WG-6 Expression BeadChip data were background
corrected in Illumina GenomeStudio, subsequent analysis proceeded using
the lumi and RankProd packages in R (Bioconductor, Seatlle, WA, USA).36–38
Variant Stabilisation Transform and Robust Spline Normalisation were
applied in lumi. Differential expression was detected using Rank Products
analysis. A list of genes for each comparison was generated using 0.05
percentage of false positives as a cutoff. Expression profiles of the 18 106
probes that passed a detection P-value filter on all of the microarrays were
used for GSEA.39 GSEA is used to determine the differences between an
experimental gene set and a selected gene list from the Molecular
Signatures Database (MSigDB, Broad Institute, Cambridge, MA, USA), an
annotated database of gene sets. GSEA can be downloaded from http://
www.broadinstitute.org/gsea/downloads.jsp.
Other statistical analyses
All studies were performed on at least three independent triplicates.
GraphPad Prism version 5 software was used to calculate unpaired
Student’s t-tests and results are reported as mean± s.e.m. P valueso0.05
were considered significant.
Antibodies
Anti-anti-p53 (#2524), JNK (#9252), phospho-SAPK/JNK (Thr183/Tyr185)
(81E11) (#4668), ERK (#9102), Phospho-p44/42 MAPK (Erk1/2) (Thr202/
Tyr204) (#4370), p100/p52 (#4882), RELB, phospho-S536 RELA (#3033),
IκB-α (#9242), active caspase 3 (#9664) and γH2A.X (#9718) were from Cell
Signaling Technology (Hitchin, UK). Anti-RELA (sc372) and c-Rel (sc71) were
from Santa Cruz (Wembley, UK). Anti-β-ACTIN (A5441) was from Sigma
(Gillingham, UK). Anti-PCNA (ab2426), and p105/p50 (ab32360) were from
Abcam (Cambridge, UK). Anti-BrdU (#347580) was from BD (Oxford, UK).
Anti-rabbit IgG (Sigma A6154 and Cell Signaling #7074) and anti-mouse
IgG (Sigma A9044) HRP-linked secondary antibodies were used for western
blot detection.
Accession numbers
Microarray data have been submitted to ArrayExpress with accession
number: E-MTAB-3596.
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Figure 7. Model showing the effects of the RelA T505A mutation. In
WT mice, tissue damage and hepatocyte loss leads to compensatory
wound healing and cell proliferation. We propose that, as a
consequence of this, DNA replication stress will lead to checkpoint
kinase activation and Chk1-mediated phosphorylation of RelA at
Thr505 (although other kinases could also perform this role). This in
turn results in suppression/modulation of RelA transcriptional
activity. However, in RelA T505A mice this pathway is defective,
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leading to an enhanced proliferative response and other effects,
resulting in earlier onset of hepatocellular carcinoma.
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